@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix go: . @prefix Protein: . @prefix pfm: . @prefix geneProductOf: . @prefix hasAgent: . @prefix species: . @prefix occursIn: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 hasAgent: sub:_2; a go:0042789 . sub:_2 geneProductOf: pfm:Mef2%20Family; a Protein: . sub:_3 occursIn: species:10090; rdf:object sub:_1; rdf:predicate belv:decreases; rdf:subject go:0007049; a rdf:Statement . sub:assertion rdfs:label "bp(GO:\"cell cycle\") -| tscript(p(PFM:\"Mef2 Family\"))" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "1.4" . sub:_4 prov:value "even though this fusion protein efficiently prevented BrdU uptake in MCK-CAT-positive cells (Figure 4h-j). As E2F1-pRb(SP) retained the anti-proliferative property of pRb but did not fully activate myogenesis on its own, we tested whether it could cooperate with MEF2C-VP16 in our myogenesis assays. The combination of MyoD+E12, MEF2C-VP16, and E2F1-pRb(SP) activated MCK-luciferase expression to a level equal to or greater than that achieved following co-transfection of MyoD+E12 with pRb (Figure 4a, compare columns 3 and 7), and led to the appearance of numerous cells in the culture that displayed very high levels of CAT staining and no BrdU incorporation (Figure 4k-m), very similar to what was observed following transfection of MyoD with pRb (Figure 4b-d). Cotransfection of E2F1-pRb(SP) and MEF2C-VP16 in the absence of MyoD did not induce the expression of MCK-CAT (data not shown). Thus, we were able to fully substitute for the loss of pRb by cotransfecting MyoD with an activated form of MEF2 and the cell-cycle-arresting molecule E2F1-pRb(SP)."; prov:wasQuotedFrom pubmed:10322110 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:10322110; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:29:47.108+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }